JP2020522521A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522521A5 JP2020522521A5 JP2019566797A JP2019566797A JP2020522521A5 JP 2020522521 A5 JP2020522521 A5 JP 2020522521A5 JP 2019566797 A JP2019566797 A JP 2019566797A JP 2019566797 A JP2019566797 A JP 2019566797A JP 2020522521 A5 JP2020522521 A5 JP 2020522521A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination
- inhibitor
- carcinoma
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 50
- 201000011510 cancer Diseases 0.000 claims description 37
- 239000003112 inhibitor Substances 0.000 claims description 27
- 201000009030 Carcinoma Diseases 0.000 claims description 26
- 102000001301 EGF receptor Human genes 0.000 claims description 23
- 108060006698 EGF receptor Proteins 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 22
- 230000001225 therapeutic effect Effects 0.000 claims description 20
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims description 18
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims description 18
- 239000000427 antigen Substances 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 12
- 239000003446 ligand Substances 0.000 claims description 12
- 150000003384 small molecules Chemical class 0.000 claims description 12
- 230000009702 cancer cell proliferation Effects 0.000 claims description 6
- 230000034994 death Effects 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 claims description 5
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 claims description 5
- 229940124647 MEK inhibitor Drugs 0.000 claims description 5
- 102000001253 Protein Kinase Human genes 0.000 claims description 5
- 108060006633 protein kinase Proteins 0.000 claims description 5
- AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 claims description 4
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 claims description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 4
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims description 4
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 4
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 229950001573 abemaciclib Drugs 0.000 claims description 4
- 208000009956 adenocarcinoma Diseases 0.000 claims description 4
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims description 4
- 229960001686 afatinib Drugs 0.000 claims description 4
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 4
- 229950004272 brigatinib Drugs 0.000 claims description 4
- 230000004611 cancer cell death Effects 0.000 claims description 4
- 230000005907 cancer growth Effects 0.000 claims description 4
- 229960005395 cetuximab Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229960002271 cobimetinib Drugs 0.000 claims description 4
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims description 4
- 229960001433 erlotinib Drugs 0.000 claims description 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 4
- 229960002584 gefitinib Drugs 0.000 claims description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 4
- 229950007440 icotinib Drugs 0.000 claims description 4
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 claims description 4
- 229960004891 lapatinib Drugs 0.000 claims description 4
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 4
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 claims description 4
- 229950010203 nimotuzumab Drugs 0.000 claims description 4
- 229960003278 osimertinib Drugs 0.000 claims description 4
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 claims description 4
- 229960004390 palbociclib Drugs 0.000 claims description 4
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims description 4
- 229960001972 panitumumab Drugs 0.000 claims description 4
- 229950003687 ribociclib Drugs 0.000 claims description 4
- -1 selmethinib Chemical compound 0.000 claims description 4
- 208000016596 serous neoplasm Diseases 0.000 claims description 4
- 229960004066 trametinib Drugs 0.000 claims description 4
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 4
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010011732 Cyst Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 208000034179 Neoplasms, Glandular and Epithelial Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 210000000013 bile duct Anatomy 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000031513 cyst Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 201000005616 epidermal appendage tumor Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 210000004602 germ cell Anatomy 0.000 claims description 2
- 230000000762 glandular Effects 0.000 claims description 2
- 210000003494 hepatocyte Anatomy 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000003849 large cell carcinoma Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000022669 mucinous neoplasm Diseases 0.000 claims description 2
- 230000009826 neoplastic cell growth Effects 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 208000000649 small cell carcinoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 208000010576 undifferentiated carcinoma Diseases 0.000 claims description 2
- 102000043136 MAP kinase family Human genes 0.000 claims 10
- 108091054455 MAP kinase family Proteins 0.000 claims 10
- 239000000890 drug combination Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 18
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/086911 WO2018218633A1 (en) | 2017-06-02 | 2017-06-02 | Combination therapies for treating cancers |
| CNPCT/CN2017/086911 | 2017-06-02 | ||
| PCT/US2018/035641 WO2018223022A1 (en) | 2017-06-02 | 2018-06-01 | Combination therapies for treating cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020522521A JP2020522521A (ja) | 2020-07-30 |
| JP2020522521A5 true JP2020522521A5 (https=) | 2021-07-26 |
Family
ID=64454257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566797A Pending JP2020522521A (ja) | 2017-06-02 | 2018-06-01 | 癌を処置するための併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12076399B2 (https=) |
| EP (1) | EP3630196A4 (https=) |
| JP (1) | JP2020522521A (https=) |
| KR (1) | KR20200011957A (https=) |
| CN (1) | CN111212662A (https=) |
| AU (1) | AU2018275118B2 (https=) |
| BR (1) | BR112019025453A2 (https=) |
| CA (1) | CA3063743A1 (https=) |
| RU (1) | RU2019143403A (https=) |
| WO (2) | WO2018218633A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| WO2018218633A1 (en) | 2017-06-02 | 2018-12-06 | Beijing Percans Oncology Co. Ltd. | Combination therapies for treating cancers |
| EP3738084A4 (en) | 2018-01-08 | 2021-11-17 | G1 Therapeutics, Inc. | SUPERIOR G1T38 DOSING SCHEMES |
| IL257225A (en) * | 2018-01-29 | 2018-04-09 | Yeda Res & Dev | Treatment of sarcoma |
| WO2019195959A1 (en) * | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
| US11633401B2 (en) | 2018-07-06 | 2023-04-25 | Memorial Sloan Kettering Cancer Center | Combination therapy with MEK inhibitor and CDK4/6 inhibitor to treat pancreatic cancer |
| CA3109605A1 (en) | 2018-08-13 | 2020-02-20 | Beijing Percans Oncology Co. Ltd. | Biomarkers for cancer therapy |
| AU2020363101A1 (en) * | 2019-10-09 | 2022-05-05 | Cothera Bioscience, Inc. | Combination therapy for cancers with KRAS mutation |
| US20230310436A1 (en) * | 2019-10-09 | 2023-10-05 | Cothera Bioscience, Inc. | Combination therapy for cancers with kras mutation |
| CN112168828A (zh) * | 2020-11-10 | 2021-01-05 | 南京医科大学 | 一种egfr与cdk4/6小分子靶向药组合物及其应用 |
| CN114939168A (zh) * | 2022-05-16 | 2022-08-26 | 复旦大学 | Cdk6抑制剂在制备预防或治疗垂体腺瘤的药物中的应用 |
| CN115029316B (zh) * | 2022-06-20 | 2024-04-30 | 华中科技大学同济医学院附属协和医院 | 一种具有放疗敏感和放疗耐受特性的原代宫颈癌细胞系及其构建方法和应用 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5976790A (en) | 1992-03-04 | 1999-11-02 | The Regents Of The University Of California | Comparative Genomic Hybridization (CGH) |
| PT699237E (pt) | 1994-03-17 | 2003-07-31 | Merck Patent Gmbh | Fvs de cadeia anti-egfr e anticorpos anti-egfr |
| KR100737090B1 (ko) | 2000-02-15 | 2007-07-06 | 아스텔라스세이야쿠 가부시키가이샤 | 축합 이미다졸륨 유도체 |
| US7132511B2 (en) | 2001-02-19 | 2006-11-07 | Merck Patent Gmbh | Modified anti-EGFR antibodies with reduced immunogenicity |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| CA2450285C (en) | 2001-06-13 | 2016-08-02 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| MXPA05011078A (es) | 2003-04-15 | 2006-01-24 | Astellas Pharma Inc | Bromuro y sus cristales. |
| TW200526684A (en) | 2003-11-21 | 2005-08-16 | Schering Corp | Anti-IGFR1 antibody therapeutic combinations |
| DE10355904A1 (de) | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Feste Formen von anti-EGFR-Antikörpern |
| WO2005094830A1 (en) | 2004-03-30 | 2005-10-13 | Pfizer Products Inc. | Combinations of signal transduction inhibitors |
| US20090253770A1 (en) | 2004-05-18 | 2009-10-08 | Kurume University | Target gene mimitin of myc |
| JP2008514635A (ja) | 2004-09-27 | 2008-05-08 | コーザン バイオサイエンシス インコーポレイテッド | 特異的キナーゼ阻害剤 |
| DK1951759T3 (da) | 2005-11-12 | 2010-05-10 | Lilly Co Eli | Anti-EGFR-antistoffer |
| JP4806776B2 (ja) | 2006-01-27 | 2011-11-02 | 国立大学法人 千葉大学 | ｃ−ｍｙｃ遺伝子転写抑制因子ＦＩＲのスプライシングバリアント又はイントロン２内の４塩基繰り返し配列による癌検出方法 |
| US7498142B2 (en) | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| US20100249413A1 (en) | 2006-08-25 | 2010-09-30 | Makoto Murai | Stabilized pharmaceutical composition |
| JP5103604B2 (ja) | 2006-10-31 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインキナーゼ阻害剤としての２−アミノチアゾール−４−カルボン酸アミド |
| US7618992B2 (en) | 2006-12-29 | 2009-11-17 | Astellas Pharma Inc. | Method of treating cancer by co-administration of anticancer agents |
| EP2225235B1 (en) | 2007-10-29 | 2017-09-06 | Merck Sharp & Dohme Corp. | Thiazole carboxamide derivatives and their use to treat cancer |
| ES2456966T3 (es) | 2007-11-12 | 2014-04-24 | Takeda Pharmaceutical Company Limited | Inhibidores de MAPK/ERK cinasa |
| WO2009146034A2 (en) | 2008-03-31 | 2009-12-03 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors and methods of use thereof |
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| WO2010056931A1 (en) | 2008-11-14 | 2010-05-20 | Intelligent Oncotherapeutics, Inc. | Methods for identification of tumor phenotype and treatment |
| US8710068B2 (en) | 2009-01-19 | 2014-04-29 | The Trustees Of The University Of Pennsylvania | Method of treating cancer using a survivin inhibitor |
| ES2576061T3 (es) | 2010-02-25 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF |
| EP2558092B1 (en) | 2010-04-13 | 2018-06-27 | Novartis AG | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| JP2014156400A (ja) | 2011-05-24 | 2014-08-28 | Astellas Pharma Inc | 腫瘍の画像診断用標識誘導体 |
| US20140228423A1 (en) | 2011-06-01 | 2014-08-14 | Baylor College Of Medicine | Biomarkers and therapy for cancer |
| FI20115876A0 (fi) | 2011-09-06 | 2011-09-06 | Turun Yliopisto | Yhdistelmähoito |
| US20130122005A1 (en) | 2011-10-27 | 2013-05-16 | Paul Adam | Anticancer combination therapy |
| EP2780354A4 (en) | 2011-11-16 | 2015-06-24 | Oncomed Pharm Inc | HUMAN NOTCH RECEPTOR MUTATIONS AND THEIR USE |
| US9662329B2 (en) | 2012-03-26 | 2017-05-30 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of survivin antagonists in polyomavirus-related disease |
| AR091876A1 (es) | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| PL2945628T3 (pl) | 2013-01-15 | 2020-09-21 | Aragon Pharmaceuticals, Inc. | Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza |
| US20160024591A1 (en) | 2013-03-14 | 2016-01-28 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer |
| MX2015010854A (es) * | 2013-03-14 | 2016-07-20 | Genentech Inc | Combinaciones de un compuesto inhibidor de mek con un compuesto inhibidor de her3/egfr y metodos de uso. |
| SG11201507427QA (en) | 2013-03-15 | 2015-10-29 | Genentech Inc | Compositions and methods for diagnosis and treatment of hepatic cancers |
| MA38522A1 (fr) * | 2013-03-21 | 2017-10-31 | Novartis Ag | Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur. |
| US9314460B1 (en) | 2013-04-09 | 2016-04-19 | Stc.Unm | Method for cancer cell reprogramming |
| KR101514877B1 (ko) | 2013-05-06 | 2015-04-24 | 조선대학교산학협력단 | ＡＰＥ/Ｒｅｆ -1 및 ＪＡＧ1/Ｎｏｔｃｈ의 대장암 진단용 마커로서의 용도 |
| US20170080093A1 (en) * | 2013-10-22 | 2017-03-23 | Tyme, Inc. | Tyrosine Derivatives And Compositions Comprising Them |
| WO2015095840A1 (en) | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of cdk and erk inhibitors |
| HUE055747T2 (hu) | 2014-04-04 | 2021-12-28 | Astrazeneca Ab | EGFR-gátló és MEK-gátló kombinációja NRAS-mutált rák kezelésében történõ alkalmazásra |
| ES2823756T3 (es) | 2014-04-16 | 2021-05-10 | Signal Pharm Llc | Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR |
| EP3392348A3 (en) | 2014-06-16 | 2018-11-21 | Worldwide Innovative Network | Method for selecting personalized tri-therapy for cancer treatment |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| US9814714B2 (en) * | 2015-05-22 | 2017-11-14 | Plexxikon Inc. | Kinase modulation, and indications therefor |
| WO2016201370A1 (en) * | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| IL256242B2 (en) | 2015-06-22 | 2024-09-01 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| US20170027951A1 (en) * | 2015-07-27 | 2017-02-02 | Southern Research Institute | Methods and compositions to treat cancers involving egfr |
| EP3340990B1 (en) * | 2015-08-28 | 2019-09-25 | Novartis AG | Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer |
| US20170114098A1 (en) * | 2015-09-03 | 2017-04-27 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| US11499972B2 (en) | 2015-09-15 | 2022-11-15 | Swedish Health Services | Methods and panels of compounds for characterization of glioblastoma multiforme tumors and cancer stem cells thereof |
| WO2017070475A1 (en) * | 2015-10-22 | 2017-04-27 | Merrimack Pharmaceuticals, Inc. | Methods of treating cancer by administering a mek inhibitor and a combination of anti-egfr antibodies |
| AU2017205478A1 (en) | 2016-01-07 | 2018-06-28 | Swadesh K. Das | A method of modulating survival and stemness of cancer stem cells by MDA-9/Syntenin (SDCBP) |
| WO2017143237A1 (en) | 2016-02-17 | 2017-08-24 | Acetylon Pharmaceuticals, Inc. | Increasing expression of interferon regulated genes with combinatons of histone deacetylase inhibitors and immunomodulatory drugs |
| CN108289885B (zh) | 2016-09-23 | 2020-10-20 | 江苏恒瑞医药股份有限公司 | 酪氨酸激酶抑制剂在制备治疗癌症药物中的用途 |
| WO2018127786A1 (en) | 2017-01-06 | 2018-07-12 | Oslo Universitetssykehus Hf | Compositions and methods for determining a treatment course of action |
| CN106822905B (zh) | 2017-03-08 | 2019-05-17 | 暨南大学 | 含Survivin抑制剂和IRE1抑制剂的药物及用途 |
| WO2018218633A1 (en) | 2017-06-02 | 2018-12-06 | Beijing Percans Oncology Co. Ltd. | Combination therapies for treating cancers |
| US12571049B2 (en) | 2018-03-21 | 2026-03-10 | Dana-Farber Cancer Institute, Inc. | Therapeutic treatment of select diffuse large B cell lymphomas exhibiting distinct pathogenic mechanisms and outcomes |
| WO2019195959A1 (en) | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
| WO2020034061A1 (en) | 2018-08-13 | 2020-02-20 | Beijing Percans Oncology Co., Ltd. | Biomarkers for cancer therapy |
| WO2020097901A1 (en) | 2018-11-16 | 2020-05-22 | Beijing Percans Oncology Co. Ltd. | Biomarkers for cancer therapy |
| CA3109605A1 (en) | 2018-08-13 | 2020-02-20 | Beijing Percans Oncology Co. Ltd. | Biomarkers for cancer therapy |
-
2017
- 2017-06-02 WO PCT/CN2017/086911 patent/WO2018218633A1/en not_active Ceased
-
2018
- 2018-06-01 KR KR1020197037178A patent/KR20200011957A/ko not_active Ceased
- 2018-06-01 EP EP18810472.3A patent/EP3630196A4/en not_active Withdrawn
- 2018-06-01 CN CN201880050028.2A patent/CN111212662A/zh active Pending
- 2018-06-01 WO PCT/US2018/035641 patent/WO2018223022A1/en not_active Ceased
- 2018-06-01 AU AU2018275118A patent/AU2018275118B2/en active Active
- 2018-06-01 BR BR112019025453-6A patent/BR112019025453A2/pt not_active Application Discontinuation
- 2018-06-01 JP JP2019566797A patent/JP2020522521A/ja active Pending
- 2018-06-01 CA CA3063743A patent/CA3063743A1/en active Pending
- 2018-06-01 US US16/617,229 patent/US12076399B2/en active Active
- 2018-06-01 RU RU2019143403A patent/RU2019143403A/ru unknown
-
2024
- 2024-07-22 US US18/779,583 patent/US20250121057A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020522521A5 (https=) | ||
| Sosa Iglesias et al. | Drug resistance in non-small cell lung cancer: a potential for NOTCH targeting? | |
| Morris et al. | Interaction of radiation therapy with molecular targeted agents | |
| Chiva et al. | A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer | |
| Lee et al. | Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling | |
| Polom et al. | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer | |
| Braun et al. | New systemic frontline treatment for metastatic colorectal carcinoma | |
| Concu et al. | Cetuximab and the head and neck squamous cell cancer | |
| RU2019143403A (ru) | Комбинированные терапии для лечения онкологических заболеваний | |
| Eskander et al. | Targeting angiogenesis in advanced cervical cancer | |
| Black et al. | Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer | |
| Doa’a et al. | A mini-review of c-Met as a potential therapeutic target in melanoma | |
| Chi et al. | Putative abscopal effect in three patients treated by combined radiotherapy and modulated electrohyperthermia | |
| Ramezani et al. | The role of kinase signaling in resistance to bevacizumab therapy for glioblastoma multiforme | |
| Tolaney | New HER2-positive targeting agents in clinical practice | |
| Griffioen et al. | The emerging quest for the optimal angiostatic combination therapy | |
| Narayanan et al. | Incorporating VEGF-targeted therapy in advanced urothelial cancer | |
| Vuky et al. | Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer | |
| Jiang et al. | Chemoradiotherapy using carboplatin plus paclitaxel versus cisplatin plus fluorouracil for esophageal or gastroesophageal junction cancer | |
| Mir et al. | Current treatment approaches to breast cancer | |
| Wadlow et al. | The role of targeted agents in preoperative chemoradiation for rectal cancer | |
| Du et al. | Gantt chart for updated OS and PFS after cancer targeted therapy | |
| Goto | Current treatment options for cutaneous adnexal malignancies | |
| Park et al. | The role of autophagy induced by pemetrexed in lung adenocarcinoma cells | |
| Esteva et al. | Gaining ground on breast cancer |